Thermo Fisher Showcases New Clinical and Research Lab Solutions at AACC 2022

The Applied Biosystems TaqMan-SARS-CoV-2 Mutation Panel enables labs to build their own custom panel from a menu of verified real-time PCR assays. This meets the evolving needs of customers and public health agencies seeking to rapidly identify and survey current mutations as well as emerging variants. To support labs as they move beyond COVID testing, Thermo Fisher is evolving its respiratory testing menu and improving automation to accelerate research. The Applied Biosystems TaqPath COVID-19, Flu A, Flu B Combo Kit helps labs expand their existing COVID-19 testing menu for respiratory samples while maintaining workflow simplicity and without increasing operational costs.

Also featured at AACC is the new Thermo Scientific KingFisher SpeciTRAX Sample Transfer System, which provides researchers in infectious diseases and genetics with an automated sample-handling system, including new features, such as an automated decapper, that relieve the sample processing bottleneck for increased throughput. A new interface with the Inpeco S.A.'s FlexLab Total Laboratory Automation system (TLA), enables primary tubes on the Inpeco LAS to be transported directly to the Thermo Scientific Cascadion SM Clinical Analyzer for automated loading, pre-treatment and analysis. This first-of-its-kind integration enables fully automated, gold-standard LC-MS/MS technology to improve clinical lab productivity.

The Thermo Scientific DRI Fentanyl II Drugs of Abuse Assay is now available on medium to high-throughput instruments, including the Indiko Plus and Mindray BS-480, Mindray BA-800M. Labs of any size can now accurately test for multiple drugs of abuse at high volume using fully automated analyzers. Thermo Fisher's broad and complementary offering of screening to confirmatory solutions also includes the Thermo Scientific Tox Explorer Collection, an all-in-one LC-MS/MS solution for toxicology. The Thermo Scientific EliA RNA Pol III and EliA Rib-P tests have received U.S. FDA clearance for aiding in the diagnosis of Systemic Sclerosis and Systemic Lupus Erythematosus. These tests are part of a broader EliA portfolio of connective tissue disease tests that help provide a clearer clinical picture for patients.

"Our latest platform and workflow innovations give clinical laboratories and researchers greater flexibility and assurance as they respond to new and existing diagnostic challenges," said Gianluca Pettiti, executive vice president, Thermo Fisher Scientific. "By minimizing hands-on time, reducing time-to-results, and improving analytical performance, we're enabling the science that shapes the future of diagnostics, as we all work toward improving patient outcomes."
 

Related Links:
Thermo Fisher Scientific Inc.